Cagrilintide (AM833)

Overview

Cagrilintide (AM833, NN9838) is a next-generation long-acting acylated amylin analog developed by Novo Nordisk for the treatment of obesity and type 2 diabetes [8][13]. It represents the first amylin-class molecule engineered for once-weekly subcutaneous administration, overcoming the major pharmacokinetic limitation of pramlintide, the only approved amylin analog, which requires three daily injections due to its short half-life of approximately 48 minutes [1][8][14].

Cagrilintide is being developed both as a monotherapy and, more prominently, as the amylin component of CagriSema, a fixed-dose combination with the GLP-1 receptor agonist semaglutide 2.4 mg [3][4]. CagriSema engages two complementary neuroendocrine satiety pathways -- amylin receptor signaling and incretin receptor signaling -- producing additive weight loss that exceeds either component alone [3][15]. In the pivotal Phase 3 REDEFINE 1 trial, CagriSema achieved 22.7% body weight reduction at 68 weeks, with 60% of participants losing at least 20% of their body weight [3]. Novo Nordisk submitted a New Drug Application (NDA) for CagriSema to the U.S. FDA in December 2025, with a regulatory decision expected by late 2026 [19].

Molecular Weight

~4409 Da (free base)

Molecular Formula

C194H312N54O59S2

Sequence

37-amino acid acylated amylin analog; pramlintide backbone with N14E, V17R, P37Y substitutions; Cys2-Cys7 disulfide; C-terminal amide

Key Modifications

N-terminal C20 eicosanedioic fatty diacid via gamma-Glu linker; N14E/V17R salt bridge; Pro25/28/29 retained from pramlintide

Half-life

159-195 hours (~7-8 days); suitable for once-weekly dosing

Receptor

AMY1R, AMY2R, AMY3R (CTR + RAMP1/2/3), and CTR; non-selective amylin/calcitonin receptor agonist

Routes Studied

Subcutaneous injection (abdomen, thigh, or upper arm), once weekly

Developer

Novo Nordisk A/S

Regulatory Status

Phase 3 (CagriSema NDA submitted to FDA December 2025; decision expected late 2026)

CAS Number

1415456-99-3

Molecular Structure and Pharmacology

Peptide Architecture

Cagrilintide is a synthetic 37-amino acid peptide with the molecular formula C194H312N54O59S2 and a molecular weight of approximately 4409 Da (CAS: 1415456-99-3) [8]. Its backbone is derived from pramlintide rather than native human amylin, a deliberate design choice to avoid the amyloid fibril formation tendency inherent to human amylin while retaining full receptor agonist activity [8][12].

The key structural features include:

• Pramlintide-derived backbone: The three proline substitutions at positions 25, 28, and 29 (Pro25, Pro28, Pro29) that define pramlintide are retained, preventing beta-sheet formation and amyloid aggregation that would otherwise occur during storage and at the injection site [8][14].
• N14E and V17R substitutions: Asparagine-14 is replaced with glutamic acid and valine-17 with arginine, creating an intra-peptide ionic lock (salt bridge) between E14 and R17 that stabilizes the central alpha-helical segment of the molecule. This conformational stabilization enhances receptor binding potency, particularly at the calcitonin receptor (CTR) [7][8][10].
• P37Y substitution: The C-terminal proline-37 is replaced with tyrosine (in some reports noted as simply proline retention), contributing to receptor engagement and peptide stability [7].
• Cys2-Cys7 disulfide bridge: The native amylin disulfide bond is preserved, maintaining the N-terminal loop structure essential for receptor interaction [8].
• C-terminal amidation: The peptide is amidated at its C-terminus, consistent with the native amylin structure and important for biological activity [8].

Fatty Diacid Acylation

The defining pharmacokinetic innovation in cagrilintide is its N-terminal acylation with a C20 eicosanedioic fatty diacid attached via a gamma-glutamic acid (gamma-Glu) linker to the lysine-1 residue [8]. This design was inspired by the success of semaglutide, where a C18 fatty diacid linker extended the half-life of a GLP-1 analog sufficiently for once-weekly dosing. Structure-activity relationship studies at Novo Nordisk identified the N-terminus as the optimal attachment point for the fatty acid, as acylation at other positions (mid-chain or C-terminal lysines) either reduced receptor potency or impaired brain penetration [8].

The fatty diacid serves three critical functions:

1. Albumin binding: The lipophilic acyl chain binds reversibly to serum albumin (and to a lesser extent to other plasma proteins), creating a circulating depot that dramatically slows renal clearance and proteolytic degradation [8][13].
2. Half-life extension: The elimination half-life increases from approximately 48 minutes (pramlintide) to 159-195 hours (cagrilintide), a greater than 200-fold improvement that enables once-weekly dosing [1][8].
3. Self-association at the injection site: The acylated peptide forms a slow-release depot at the subcutaneous injection site, further extending absorption kinetics [8].

The selection of a C20 fatty diacid (rather than a C18 monoacid as used in liraglutide) was motivated by observations that diacid conjugation produced higher potency and longer duration of action compared to monoacid conjugation in both GLP-1 and amylin analog series [8].

Receptor Pharmacology

Cagrilintide is a non-selective agonist of the calcitonin family of G protein-coupled receptors, activating all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR) itself [7][10]. The amylin receptors are heterodimers composed of the calcitonin receptor associated with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), each producing distinct tissue expression patterns and signaling characteristics [7][12].

In cell-based assays comparing cagrilintide with six other calcitonin family agonists, AM833 demonstrated potent activation across all receptor subtypes, with notably enhanced activity at CTR compared to pramlintide [7]. The structural basis for this enhanced CTR potency involves the R17-E14 ionic lock, which stabilizes the peptide conformation for optimal receptor engagement, and the effects of N-terminal acylation on the peptide's orientation within the receptor binding pocket [7][10].

Cryo-EM structural studies published in 2025 revealed that cagrilintide binds to calcitonin and amylin receptors via a conserved "bypass" motif involving mid-segment residues, with the fatty acid moiety extending away from the receptor binding interface and interacting with the extracellular environment and albumin [10].

Mechanism of Action

Central Appetite Regulation

Cagrilintide exerts its weight-reducing effects primarily through activation of amylin receptors in the central nervous system [9][12][16]. Native amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient intake. It acts on receptors concentrated in several brain regions critical for appetite and energy homeostasis:

• Area postrema (AP): This circumventricular organ in the hindbrain lacks a complete blood-brain barrier and is the primary site of amylin-mediated satiety signaling. Amylin receptor activation in the AP triggers neuronal cascades that promote meal termination and reduce meal size [9][12][16].
• Nucleus of the solitary tract (NTS): Closely connected to the area postrema, neurons in the NTS relay amylin-derived satiety signals to higher brain centers, integrating information about meal consumption and gastrointestinal status [12][16].
• Arcuate nucleus of the hypothalamus: Amylin receptors in this region participate in longer-term energy balance regulation, modulating neuropeptide expression (including NPY/AgRP and POMC/CART pathways) to reduce hunger drive [9][12].
• Ventral tegmental area and laterodorsal tegmental nucleus: These reward-related brain regions express amylin receptors that modulate the hedonic (pleasure-driven) aspects of food intake, potentially reducing cravings and food reward signaling [12][16].

A 2025 preclinical study demonstrated that cagrilintide lowers body weight specifically through brain AMY1R and AMY3R, with a single dose reducing food intake for 48-60 hours compared to only 6 hours for an equivalent pramlintide dose [9]. This dramatically prolonged central activity reflects both the extended plasma half-life from acylation and potentially enhanced receptor engagement kinetics.

Complementary Mechanisms with GLP-1 Agonism

The combination of cagrilintide with semaglutide (CagriSema) engages two distinct but overlapping neural satiety pathways [3][15][17]:

• Amylin pathway (cagrilintide): Acts primarily through area postrema and hypothalamic amylin receptors to reduce food intake via both homeostatic and hedonic mechanisms.
• Incretin pathway (semaglutide): Acts through GLP-1 receptors in the hypothalamus, brainstem, and vagal afferents to suppress appetite, delay gastric emptying, and enhance glucose-dependent insulin secretion.

The additive weight loss observed with CagriSema (22.7%) exceeding the sum of individual component effects (cagrilintide 11.8% + semaglutide 16.1% individually, noting overlap) suggests synergistic interaction between these pathways at the neural circuit level [3][15]. Both agents also independently slow gastric emptying and suppress glucagon secretion, contributing to glycemic control [4][17].

Peripheral Metabolic Effects

Beyond central appetite suppression, amylin receptor agonism produces several peripheral metabolic effects:

• Glucagon suppression: Cagrilintide reduces postprandial glucagon secretion, contributing to improved glucose homeostasis [4][12].
• Gastric emptying delay: Amylin receptor activation slows gastric emptying, prolonging nutrient exposure in the upper gastrointestinal tract and promoting satiety signals [12][16].
• Potential effects on energy expenditure: Preclinical evidence suggests amylin receptor signaling may influence thermogenesis and energy expenditure, although this has not been definitively established in human studies [12].

Researched Applications

Obesity Without Type 2 Diabetes (Strong Evidence)

Phase 2 Monotherapy Trial: The dose-finding trial enrolled 706 adults with overweight or obesity (without diabetes) at 57 sites across 10 countries, randomizing them to one of five cagrilintide doses (0.3, 0.6, 1.2, 2.4, or 4.5 mg weekly), liraglutide 3.0 mg daily, or placebo for 26 weeks [1]. Mean percentage weight reductions were dose-dependent: 6.0% (0.3 mg), 6.8% (0.6 mg), 9.1% (1.2 mg), 9.4% (2.4 mg), and 10.8% (4.5 mg), compared to 3.0% with placebo [1]. The highest cagrilintide dose (4.5 mg) achieved statistically superior weight loss compared to liraglutide 3.0 mg daily (10.8% vs 9.0%) despite liraglutide being an already-approved obesity medication [1]. Gastrointestinal adverse events occurred in 41-63% of cagrilintide groups versus 32% with placebo, with nausea as the most common event (20-47% vs 18%) [1].

REDEFINE 1 (Pivotal Phase 3): This landmark trial randomized 3,417 adults with obesity or overweight to four treatment arms: CagriSema, cagrilintide 2.4 mg alone, semaglutide 2.4 mg alone, or placebo, all administered once weekly for 68 weeks [3]. The results demonstrated:

• CagriSema: 22.7% mean weight loss (on-treatment) and 20.4% (treatment-policy estimand, including all participants regardless of adherence)
• Cagrilintide 2.4 mg alone: 11.8% weight loss
• Semaglutide 2.4 mg alone: 16.1% weight loss
• Placebo: 2.3% weight loss

The proportion of participants achieving clinically meaningful weight loss thresholds was substantially higher with CagriSema: 60% achieved at least 20% weight loss (vs 6% cagrilintide, 27% semaglutide, 0.9% placebo), 40.4% achieved at least 25% (vs 6.0%, 16.2%, 0.9%), and 23% achieved at least 30% weight loss [3]. Significant improvements were observed in systolic blood pressure, waist circumference, lipid profiles, and glycemic markers, with 88% of participants who had prediabetes at baseline returning to normoglycemia [3][21].

Obesity with Type 2 Diabetes (Strong Evidence)

REDEFINE 2: This Phase 3 trial evaluated CagriSema versus placebo in 1,200 adults with type 2 diabetes (HbA1c 7-10%) and overweight or obesity across 12 countries over 68 weeks [4]. CagriSema achieved a mean weight reduction of 13.7% compared to 3.4% with placebo (treatment difference: -10.4 percentage points) [4]. The glycemic effects were also notable: 73.5% of CagriSema-treated patients achieved HbA1c of 6.5% or lower versus 15.9% with placebo [4]. The attenuated weight loss compared to REDEFINE 1 (13.7% vs 22.7%) is consistent with the well-established pattern across incretin-based therapies of reduced weight loss efficacy in populations with type 2 diabetes [4][15].

Phase 2 CagriSema in T2D: An earlier Phase 2 trial confirmed that co-administered cagrilintide 2.4 mg and semaglutide 2.4 mg produced superior HbA1c reduction and weight loss compared to either component alone in patients with type 2 diabetes, providing the rationale for the Phase 3 REDEFINE program [2].

Cardiovascular Outcomes (Ongoing)

REDEFINE 3: An event-driven cardiovascular outcomes trial is evaluating CagriSema versus placebo in approximately 7,000 adults with established cardiovascular disease and obesity (with or without type 2 diabetes) [5]. The primary endpoint is time to first MACE-3 event (cardiovascular death, myocardial infarction, or stroke), with a treatment period of up to 156 weeks and total study duration of approximately 4.5 years [5]. Results are anticipated in late 2027 or beyond. Given that semaglutide has independently demonstrated cardiovascular risk reduction in the SELECT trial, the cardiovascular profile of CagriSema is of significant clinical interest.

Head-to-Head Comparison with Tirzepatide (Moderate Evidence)

REDEFINE 4: This open-label Phase 3b trial directly compared CagriSema with tirzepatide 15 mg (the maximum approved dose of the dual GIP/GLP-1 receptor agonist marketed as Zepbound) in 809 adults with obesity and comorbidities over 84 weeks [6]. CagriSema achieved 23.0% weight loss versus 25.5% with tirzepatide (on-treatment estimand), or 20.2% versus 23.6% (treatment-policy estimand) [6]. The primary endpoint of noninferiority was not met, meaning the trial did not demonstrate that CagriSema was statistically equivalent to tirzepatide for weight loss [6]. While CagriSema produced clinically meaningful weight loss, tirzepatide showed a numerical advantage of approximately 2.5 percentage points [6]. Both treatments demonstrated comparable safety profiles with predominantly mild-to-moderate gastrointestinal adverse events.

Clinical Evidence Summary

The clinical evidence for cagrilintide spans a complete development trajectory from preclinical pharmacology through pivotal Phase 3 trials:

| Trial | N | Duration | Comparator | Weight Loss (CagriSema/Cagrilintide) | Key Secondary Outcome | |-------|---|----------|------------|--------------------------------------|----------------------| | Phase 2 Monotherapy [1] | 706 | 26 wk | Placebo, Liraglutide | 10.8% (4.5 mg mono) | Superior to liraglutide 3.0 mg | | Phase 2 CagriSema T2D [2] | -- | 32 wk | Components alone | Superior combination | HbA1c superiority | | REDEFINE 1 [3] | 3417 | 68 wk | Components, Placebo | 22.7% (CagriSema) | 60% achieved >=20% loss | | REDEFINE 2 [4] | 1200 | 68 wk | Placebo | 13.7% (CagriSema) | 73.5% HbA1c ≤6.5% | | REDEFINE 4 [6] | 809 | 84 wk | Tirzepatide 15 mg | 23.0% (CagriSema) | Noninferiority not met |

The data consistently demonstrate that cagrilintide as a monotherapy produces meaningful weight loss exceeding that of liraglutide, while CagriSema achieves weight loss in the 20-23% range in non-diabetic populations, establishing it as one of the most effective pharmacological weight management approaches evaluated to date [3][11][21].

Comparison with Related Therapies

Cagrilintide vs Pramlintide

Cagrilintide and pramlintide share a common 37-amino acid amylin analog backbone with the same anti-aggregation proline substitutions (Pro25/28/29), but differ fundamentally in pharmacokinetics and clinical utility [8][14]:

• Half-life: Pramlintide has a half-life of approximately 48 minutes, requiring three daily injections with meals. Cagrilintide's half-life of 159-195 hours permits once-weekly dosing [1][8].
• Weight loss potency: Pramlintide produces modest weight loss of 3-8% over extended treatment periods. Cagrilintide monotherapy achieves 10-12% weight loss [1][13].
• Receptor profile: Cagrilintide demonstrates enhanced potency at the calcitonin receptor (CTR) due to its E14-R17 salt bridge and N-terminal acylation effects, potentially broadening its pharmacological activity [7][10].
• Indication: Pramlintide is approved exclusively as an adjunct to insulin in diabetes. Cagrilintide is being developed primarily for obesity, both alone and in combination with semaglutide [13][14].

CagriSema vs Tirzepatide

These represent two distinct pharmacological approaches to combination-mechanism obesity treatment [6][17]:

• CagriSema combines an amylin analog (cagrilintide) with a GLP-1 receptor agonist (semaglutide), engaging amylin receptors and GLP-1 receptors.
• Tirzepatide is a single molecule that simultaneously activates GIP receptors and GLP-1 receptors.

In the head-to-head REDEFINE 4 trial, tirzepatide 15 mg demonstrated numerically greater weight loss than CagriSema (25.5% vs 23.0%), though both agents produced clinically impressive results [6]. The approaches are not directly comparable mechanistically: CagriSema acts through amylin-mediated satiety in the area postrema, while tirzepatide leverages GIP-mediated effects on adipose tissue metabolism and insulin sensitivity in addition to shared GLP-1 receptor effects [6][17].

Safety Profile

Gastrointestinal Adverse Events

Consistent with both the amylin and GLP-1 receptor agonist classes, gastrointestinal events are the most frequently reported adverse effects with cagrilintide-containing regimens [1][3][4][11]:

• REDEFINE 1: GI adverse events occurred in 79.6% of CagriSema participants versus 39.9% with placebo. The most common events were nausea (~41%), diarrhea (~23%), vomiting (~20%), and constipation (~18%) [3].
• REDEFINE 2: GI adverse events in 72.5% of CagriSema participants versus 34.4% with placebo, with most events being transient and mild-to-moderate [4].
• Phase 2 monotherapy: GI events in 41-63% of cagrilintide groups versus 32% with placebo, with nausea predominating (20-47% vs 18%) [1].

These events are predominantly dose-dependent, occur during the dose-escalation phase, and diminish substantially with continued treatment. The gradual dose-escalation protocol used in the REDEFINE trials was specifically designed to improve gastrointestinal tolerability [3][4].

Injection Site Reactions

A higher incidence of injection-site reactions has been observed with cagrilintide-containing regimens (CagriSema and cagrilintide alone) compared to semaglutide alone or placebo [3]. These reactions are typically mild, localized, and transient, likely related to the depot-forming properties of the acylated peptide at the injection site [3][11].

Serious Adverse Events

In the REDEFINE program, serious adverse events were more common with CagriSema than with placebo, though the overall incidence was low [3][4]. Across the combined REDEFINE 1 and REDEFINE 2 trials, six deaths occurred, all in the CagriSema groups, including one suicide in each trial [3][4]. The clinical significance of these events in the context of large trial populations requires further evaluation in the ongoing REDEFINE 3 cardiovascular outcomes trial and post-marketing surveillance if approved.

Pancreatitis and Pancreatic Safety

As with other incretin-based therapies, cases of pancreatitis have been monitored in cagrilintide trials. No significant signal for acute pancreatitis has been identified beyond what is expected with GLP-1 receptor agonists [3][4][11].

Development History and Regulatory Status

Cagrilintide was developed at Novo Nordisk through systematic structure-activity relationship studies aimed at creating a long-acting amylin analog suitable for combination with semaglutide [8]. The development trajectory includes:

• Preclinical development: Extensive medicinal chemistry optimization identified N-terminal acylation with a C20 fatty diacid via gamma-Glu linker as the optimal configuration, balancing receptor potency, half-life extension, and brain penetration [8].
• Phase 1: Initial human pharmacokinetic and safety studies confirmed the target half-life of 159-195 hours and tolerability across dose ranges.
• Phase 2 (2021): The monotherapy dose-finding trial established proof of concept with dose-dependent weight loss up to 10.8% at 26 weeks [1]. The Phase 2 CagriSema trial in type 2 diabetes confirmed combination superiority [2].
• Phase 3 REDEFINE program (2023-ongoing): Initiated with REDEFINE 1 (obesity), REDEFINE 2 (T2D and obesity), REDEFINE 3 (cardiovascular outcomes), and REDEFINE 4 (head-to-head vs tirzepatide).
• NDA submission (December 2025): Novo Nordisk submitted a New Drug Application to the U.S. FDA for CagriSema based on the REDEFINE 1 and REDEFINE 2 pivotal trials [19].
• REDEFINE 4 results (February 2026): The head-to-head comparison with tirzepatide did not meet its primary endpoint of noninferiority, though CagriSema demonstrated 23% weight loss [6].
• Expected FDA decision: Late 2026 [19].

If approved, CagriSema would become the first injectable combination of a GLP-1 receptor agonist and an amylin analog, and the first approved medication to engage the amylin receptor pathway specifically for obesity treatment [19].

Pharmacokinetics

Absorption and Distribution

Cagrilintide is administered exclusively by subcutaneous injection. Following a single SC dose, absorption from the injection site is slow and prolonged due to the depot-forming properties of the acylated peptide. Time to maximum plasma concentration (Tmax) is approximately 24-72 hours after injection, reflecting the gradual release from the subcutaneous depot and the slow dissociation of cagrilintide from the albumin-bound compartment [8][13].

The volume of distribution has not been precisely reported in published human PK studies, but is expected to be small and primarily intravascular, given the high degree of albumin binding characteristic of fatty acid-acylated peptides. By analogy with semaglutide (which uses a similar C18 fatty diacid albumin-binding strategy and has a Vd of approximately 12.5 L), cagrilintide's distribution is anticipated to be limited to the plasma and interstitial fluid compartments [8][14].

Protein Binding and Half-Life Extension Mechanism

The C20 eicosanedioic fatty diacid conjugated to cagrilintide's N-terminus binds reversibly to human serum albumin with high affinity. This albumin association is the principal mechanism of half-life extension, creating a circulating reservoir of drug that is protected from renal filtration (albumin's molecular weight of 66.5 kDa exceeds the glomerular filtration threshold) and from enzymatic degradation by plasma proteases [8][13].

The elimination half-life of cagrilintide is 159-195 hours (~6.6-8.1 days), representing a greater than 200-fold improvement over pramlintide's half-life of approximately 48 minutes [1][8]. This pharmacokinetic profile enables once-weekly dosing with stable steady-state plasma concentrations achieved by approximately week 4-5 of weekly dosing. At steady state, the peak-to-trough fluctuation is modest, maintaining receptor engagement throughout the dosing interval [8][14].

Metabolism and Elimination

Cagrilintide is primarily metabolized through proteolytic degradation of the peptide backbone and beta-oxidation of the fatty acid moiety, similar to other acylated peptide therapeutics. The peptide does not undergo significant cytochrome P450-mediated metabolism, which minimizes the potential for drug-drug interactions through CYP enzyme inhibition or induction [8][13].

Renal excretion of intact cagrilintide is minimal due to extensive albumin binding. The primary elimination pathway involves gradual proteolysis followed by amino acid recycling and fatty acid oxidation. Specific data on the effects of hepatic or renal impairment on cagrilintide pharmacokinetics have not been published in detail, though the REDEFINE trials included patients with mild-to-moderate renal impairment without dose adjustment [3][4].

CagriSema Combination Pharmacokinetics

When co-administered as CagriSema, the pharmacokinetic profiles of cagrilintide and semaglutide do not appear to exhibit clinically significant mutual interactions. Both peptides utilize albumin binding for half-life extension (cagrilintide via C20 diacid, semaglutide via C18 diacid), but the albumin binding capacity is sufficiently large (albumin concentration approximately 35-50 g/L in plasma, with multiple fatty acid binding sites) that competition for binding sites is not expected to alter the PK of either component at therapeutic concentrations [2][8]. Both components reach steady state within approximately 4-5 weeks of once-weekly dosing, and the fixed-dose combination formulation delivers consistent co-exposure from a single injection [3][4].

Dose-Response Relationships

Weight Loss Dose-Response (Monotherapy)

The Phase 2 monotherapy dose-finding trial provided a well-characterized dose-response curve for cagrilintide across five dose levels over 26 weeks [1]:

| Dose (mg weekly) | Mean Weight Loss (%) | Difference vs. Placebo (pp) | Proportion Achieving 10% or Greater Loss | |---|---|---|---| | Placebo | -3.0% | -- | ~5% | | 0.3 mg | -6.0% | -3.0 | Not reported individually | | 0.6 mg | -6.8% | -3.8 | Not reported individually | | 1.2 mg | -9.1% | -6.1 | Not reported individually | | 2.4 mg | -9.4% | -6.4 | ~35% | | 4.5 mg | -10.8% | -7.8 | ~45% |

The dose-response curve demonstrates a clear positive relationship between dose and efficacy, though with diminishing incremental benefit at the higher end: the jump from 1.2 mg to 2.4 mg added only 0.3 percentage points, while the jump from 2.4 mg to 4.5 mg added 1.4 percentage points [1]. The selection of 2.4 mg for the Phase 3 CagriSema combination was based on a benefit-risk assessment, as gastrointestinal adverse events also increased with dose (nausea: 20% at 0.3 mg to 47% at 4.5 mg vs. 18% placebo) [1][8].

CagriSema Dose-Response (Component Contribution)

The REDEFINE 1 trial provided a factorial-like design that elucidated the contribution of each CagriSema component at the 2.4 mg dose level [3]:

| Treatment Arm | Mean Weight Loss (On-Treatment) | Difference vs. Placebo | |---|---|---| | Placebo | -2.3% | -- | | Cagrilintide 2.4 mg alone | -11.8% | -9.5 pp | | Semaglutide 2.4 mg alone | -16.1% | -13.8 pp | | CagriSema (2.4/2.4 mg) | -22.7% | -20.4 pp |

The CagriSema combination effect (20.4 pp vs. placebo) exceeds the simple arithmetic sum of individual placebo-subtracted effects (9.5 + 13.8 = 23.3 pp), though this comparison must be interpreted cautiously because the individual arms share the same placebo group. Nevertheless, the data demonstrate meaningful additivity between amylin and GLP-1 receptor pathways [3][15].

Glycemic Dose-Response

In REDEFINE 2 (patients with type 2 diabetes), CagriSema produced substantial glycemic improvements: 73.5% of patients achieved HbA1c of 6.5% or lower versus 15.9% with placebo, with a mean HbA1c reduction of approximately 1.5 percentage points [4]. The attenuated weight loss in diabetic populations (13.7% vs. 22.7% in non-diabetic) is consistent with findings across all incretin-based therapies and is thought to reflect metabolic differences in insulin-resistant states [4][15].

Comparative Effectiveness

Cagrilintide Monotherapy vs. Pramlintide

Cagrilintide and pramlintide share a common amylin analog backbone but differ fundamentally in pharmacokinetics and clinical utility [8][14]:

| Parameter | Pramlintide (Symlin) | Cagrilintide | |---|---|---| | Half-life | ~48 minutes | 159-195 hours (200x longer) | | Dosing frequency | Three times daily with meals | Once weekly | | Weight loss (monotherapy) | 3-8% over 6-12 months | 10.8% over 26 weeks (4.5 mg) | | CTR potency | Lower | Enhanced (E14-R17 salt bridge) | | Approval status | FDA-approved (diabetes adjunct) | Investigational | | Route | Subcutaneous (3x daily) | Subcutaneous (1x weekly) | | Duration of central action (preclinical) | ~6 hours (single dose) | 48-60 hours (single dose) [9] |

The dramatically prolonged central activity of cagrilintide -- 48-60 hours of food intake reduction from a single dose versus 6 hours for pramlintide [9] -- reflects both the extended plasma half-life from acylation and potentially enhanced receptor engagement kinetics from the stabilized peptide conformation.

CagriSema vs. Semaglutide 2.4 mg (Wegovy)

In REDEFINE 1, CagriSema demonstrated a 6.6 percentage point greater weight loss than semaglutide 2.4 mg alone (22.7% vs. 16.1%, on-treatment) [3]. This advantage was consistent across weight loss thresholds: 60% vs. 27% achieved 20% or more weight loss, 40.4% vs. 16.2% achieved 25% or more, and 23% vs. 7.2% achieved 30% or more [3]. The addition of the amylin pathway thus meaningfully expanded the proportion of patients reaching surgically-comparable weight loss outcomes.

CagriSema vs. Tirzepatide 15 mg (Zepbound)

The head-to-head REDEFINE 4 trial (open-label, 809 participants, 84 weeks) found [6]:

| Outcome | CagriSema | Tirzepatide 15 mg | Difference | |---|---|---|---| | Weight loss (on-treatment) | -23.0% | -25.5% | -2.5 pp favoring tirzepatide | | Weight loss (treatment-policy) | -20.2% | -23.6% | -3.4 pp favoring tirzepatide | | Primary endpoint (noninferiority) | Not met | -- | -- |

Although CagriSema did not achieve noninferiority versus tirzepatide, both agents produced clinically meaningful weight loss exceeding 20%. The agents engage different complementary mechanisms -- CagriSema acts through amylin + GLP-1 receptors while tirzepatide engages GIP + GLP-1 receptors -- and have distinct safety profiles [6][17]. Factors such as cardiovascular outcomes (REDEFINE 3 ongoing), metabolic effects in diabetic populations, and tolerability differences may ultimately differentiate these approaches.

Positioning in the Weight Loss Landscape

| Agent | Mechanism | Weight Loss (Pivotal Trial) | Approval Status | |---|---|---|---| | Liraglutide 3.0 mg (Saxenda) | GLP-1R agonist | ~8% (SCALE) | FDA-approved | | Semaglutide 2.4 mg (Wegovy) | GLP-1R agonist | ~15-17% (STEP) | FDA-approved | | Tirzepatide (Zepbound) | GIP/GLP-1R dual agonist | ~21-26% (SURMOUNT) | FDA-approved | | CagriSema | Amylin + GLP-1R agonist | ~22.7% (REDEFINE 1) | NDA submitted Dec 2025 | | Cagrilintide monotherapy | Amylin receptor agonist | ~10.8% (Phase 2) | Investigational |

Enhanced Safety Profile

Gastrointestinal Tolerability by Treatment Phase

GI adverse events follow a predictable temporal pattern in cagrilintide-containing regimens, with the highest incidence during the dose-escalation phase and substantial attenuation during maintenance [3][4][11]:

REDEFINE 1 GI adverse event timeline:

• During dose escalation (weeks 1-16): The majority of nausea, vomiting, and diarrhea events occurred during this period, coinciding with stepwise dose increases
• During maintenance (week 16 onward): GI event rates declined substantially, with most patients reporting resolution of initial symptoms
• Overall: 79.6% of CagriSema participants experienced at least one GI event, but most were mild-to-moderate and transient [3]

GI adverse event rates by treatment arm (REDEFINE 1):

| Event | CagriSema | Cagrilintide 2.4 mg | Semaglutide 2.4 mg | Placebo | |---|---|---|---|---| | Any GI event | 79.6% | 63.8% | 72.4% | 39.9% | | Nausea | ~41% | ~30% | ~38% | ~14% | | Diarrhea | ~23% | ~15% | ~21% | ~12% | | Vomiting | ~20% | ~12% | ~16% | ~5% | | Constipation | ~18% | ~15% | ~16% | ~8% |

Injection Site Reactions

Injection site reactions are more common with cagrilintide-containing regimens compared to semaglutide alone, likely reflecting the depot-forming properties of the C20 fatty diacid conjugate at the SC injection site. In REDEFINE 1, injection site reactions occurred in approximately 12-15% of patients receiving cagrilintide (alone or in CagriSema) versus 4-5% with semaglutide alone or placebo [3][11]. These reactions are typically mild, localized erythema or induration, and resolve spontaneously within days.

Cardiovascular Safety Signals

Across the REDEFINE program, CagriSema demonstrated consistent improvements in cardiovascular risk markers [3][4]:

• Systolic blood pressure: 5-7 mmHg reduction beyond placebo
• Waist circumference: 12-16 cm reduction beyond placebo
• Triglycerides: Significant reductions
• LDL cholesterol: Modest reductions
• 88% of participants with prediabetes at baseline in REDEFINE 1 returned to normoglycemia

The ongoing REDEFINE 3 cardiovascular outcomes trial (approximately 7,000 patients, MACE-3 primary endpoint) will definitively address whether these surrogate improvements translate into reduced cardiovascular events [5].

Serious Adverse Events and Deaths

In the combined REDEFINE 1 and REDEFINE 2 trials, six deaths occurred, all in CagriSema treatment groups, including one suicide in each trial [3][4]. While numerically concerning, the overall incidence relative to the large trial populations (greater than 4,600 participants) falls within rates observed in other large obesity pharmacotherapy trials. The potential for neuropsychiatric effects warrants monitoring, as both amylin and GLP-1 receptors are expressed in brain regions involved in mood regulation. Causality assessment is pending the larger REDEFINE 3 dataset.

Pancreatitis and Gallbladder Events

Pancreatitis rates were monitored across all REDEFINE trials with no significant signal beyond background rates expected with GLP-1 receptor agonists [3][4][11]. Cholelithiasis (gallstones) and cholecystitis, known class effects of rapid weight loss and GLP-1 receptor agonism, were reported at rates consistent with other weight loss therapies producing comparable weight reductions.

Discontinuation Rates

Treatment discontinuation due to adverse events in REDEFINE 1 was approximately 6-8% with CagriSema versus 3-4% with placebo, with GI events being the most common reason for discontinuation [3]. These rates are comparable to those seen with semaglutide 2.4 mg in the STEP program and tirzepatide in the SURMOUNT program.

Dosing and Administration

Cagrilintide is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm [1][3]. In the CagriSema formulation, cagrilintide 2.4 mg and semaglutide 2.4 mg are delivered in a single injection [3][4].

The REDEFINE program employed a gradual dose-escalation protocol to minimize gastrointestinal adverse events, starting at cagrilintide 0.15 mg + semaglutide 0.15 mg and escalating over approximately 16 weeks to the target maintenance dose of 2.4 mg/2.4 mg [3][4]. This approach mirrors the dose-escalation strategy used successfully with other incretin-based therapies and was effective in reducing the incidence and severity of nausea and vomiting during treatment initiation.

In the Phase 2 monotherapy trial, cagrilintide doses of 0.3-4.5 mg weekly were evaluated, with 2.4 mg ultimately selected as the optimal dose for the combination therapy based on the balance of efficacy, tolerability, and pharmacokinetic considerations [1][8].